» Articles » PMID: 14680081

Longitudinal Changes in the Nature, Severity and Frequency of COPD Exacerbations

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2003 Dec 19
PMID 14680081
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Exacerbations are an important feature and outcome measure in chronic obstructive pulmonary disease (COPD), but little is known about changes in their severity, recovery, symptom composition or frequency over time. In this study 132 patients (91 male; median age 68.4 yrs and median forced expiratory volume in one second (FEV1) 38.4% predicted) recorded daily symptoms and morning peak expiratory flow. Patients were monitored for a median of 918 days and 1,111 exacerbations were identified. Patients with severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) category III, n=38) had an annual exacerbation frequency of 3.43 x yr(-1), 0.75 x yr(-1) higher than those with moderate COPD (GOLD II, n=94). Exacerbation frequency did not change significantly during the study. At exacerbation onset, symptom count increased to 2.23, relative to a baseline of 0.36 set 8-14 days previously, and this increase rose by 0.05 x yr(-1). Recovery to baseline levels in symptoms and FEV1 took longer (0.32 and 0.55 days x yr(-1)). Sputum purulence at exacerbation became more prevalent over time by 4.1% x yr(-1) from an initial value of 17%. The results of this study suggest that over time, individual patients have more symptoms during exacerbations, with an increased chance of sputum purulence and longer recovery times.

Citing Articles

Treatment patterns in patients with newly diagnosed COPD in the USA.

Anzueto A, Rogers S, Donato B, Jones B, Modi K, Olopoenia A BMC Pulm Med. 2024; 24(1):395.

PMID: 39153976 PMC: 11330015. DOI: 10.1186/s12890-024-03194-4.


DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.

Singh D, Litewka D, Paramo R, Rendon A, Sayiner A, Tanni S Adv Ther. 2023; 40(10):4282-4297.

PMID: 37382864 PMC: 10499693. DOI: 10.1007/s12325-023-02583-1.


Patient-Reported Pulmonary Symptoms, Exacerbations, and Management in a Cohort of Patients With Alpha-1 Antitrypsin Deficiency.

Choate R, Sandhaus R, Holm K, Mannino D, Strange C Chronic Obstr Pulm Dis. 2022; 9(4):549-561.

PMID: 36103189 PMC: 9718576. DOI: 10.15326/jcopdf.2022.0317.


Identification of Epitopes on Rhinovirus 89 Capsid Proteins Capable of Inducing Neutralizing Antibodies.

Niespodziana K, Cabauatan C, Pazderova P, Vacal P, Wortmann J, Keller W Int J Mol Sci. 2022; 23(9).

PMID: 35563505 PMC: 9100655. DOI: 10.3390/ijms23095113.


International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials.

Calverley P, Martinez F, Vestbo J, Jenkins C, Wise R, Lipson D Am J Respir Crit Care Med. 2022; 206(1):25-33.

PMID: 35363593 PMC: 9954323. DOI: 10.1164/rccm.202111-2630OC.